中国全科医学
中國全科醫學
중국전과의학
CHINESE GENERAL PRACTICE
2015年
2期
172-175
,共4页
唐孝庆%张程%叶贤伟%刘维佳%张湘燕
唐孝慶%張程%葉賢偉%劉維佳%張湘燕
당효경%장정%협현위%류유가%장상연
肺疾病,慢性阻塞性%卡介菌多糖核酸%核仁区酸性非组蛋白%T 淋巴细胞%免疫
肺疾病,慢性阻塞性%卡介菌多糖覈痠%覈仁區痠性非組蛋白%T 淋巴細胞%免疫
폐질병,만성조새성%잡개균다당핵산%핵인구산성비조단백%T 림파세포%면역
Pulmonary disease,chronic obstructive%BCG - polysaccharide nucleic acid%Argyrophilic nucleolar organizer proteins%T - lymphocytes%Immunity
目的:探讨卡介菌多糖核酸对慢性阻塞性肺疾病( COPD)患者 T 淋巴细胞核仁区酸性非组蛋白(Ag - NORs)水平的影响。方法选择2012年1月—2013年6月贵州省人民医院呼吸与危重症医学科及干部医疗科收治的 COPD 急性加重期( AECOPD)患者50例及在两科室治疗后 COPD 稳定期患者40例。采用随机数字表法将AECOPD 患者和 COPD 稳定期患者分别分为治疗组和对照组。AECOPD 及 COPD 稳定期对照组患者均仅给予常规治疗,治疗组患者在常规治疗基础上加用卡介菌多糖核酸治疗,疗程均为1个月。于治疗前后均对患者外周血 T 淋巴细胞Ag - NORs进行染色分析,以核仁银染面积/核银染面积( I/ S%)作为 Ag - NORs 的检测指标。结果治疗前, AECOPD 治疗组和 AECOPD 对照组外周血 T 淋巴细胞Ag - NORs水平比较,差异无统计学意义(P >0.05);治疗后, AECOPD 治疗组外周血 T 淋巴细胞Ag - NORs水平高于 AECOPD 对照组(t =-1.708,P <0.05)。治疗前,COPD 稳定期治疗组和 COPD 稳定期对照组外周血 T 淋巴细胞Ag - NORs水平比较,差异无统计学意义( P >0.05);治疗后, COPD 稳定期治疗组外周血 T 淋巴细胞Ag - NORs水平高于 COPD 稳定期对照组(t =-1.647,P <0.05)。AECOPD 治疗组及 COPD 稳定期治疗组治疗期间各出现注射部位局部红肿1例,予热敷后1周内自然消退,其他均未出现明显不良反应。结论 COPD 患者使用卡介菌多糖核酸治疗,可增加 T 淋巴细胞Ag - NORs水平,改善其免疫功能。
目的:探討卡介菌多糖覈痠對慢性阻塞性肺疾病( COPD)患者 T 淋巴細胞覈仁區痠性非組蛋白(Ag - NORs)水平的影響。方法選擇2012年1月—2013年6月貴州省人民醫院呼吸與危重癥醫學科及榦部醫療科收治的 COPD 急性加重期( AECOPD)患者50例及在兩科室治療後 COPD 穩定期患者40例。採用隨機數字錶法將AECOPD 患者和 COPD 穩定期患者分彆分為治療組和對照組。AECOPD 及 COPD 穩定期對照組患者均僅給予常規治療,治療組患者在常規治療基礎上加用卡介菌多糖覈痠治療,療程均為1箇月。于治療前後均對患者外週血 T 淋巴細胞Ag - NORs進行染色分析,以覈仁銀染麵積/覈銀染麵積( I/ S%)作為 Ag - NORs 的檢測指標。結果治療前, AECOPD 治療組和 AECOPD 對照組外週血 T 淋巴細胞Ag - NORs水平比較,差異無統計學意義(P >0.05);治療後, AECOPD 治療組外週血 T 淋巴細胞Ag - NORs水平高于 AECOPD 對照組(t =-1.708,P <0.05)。治療前,COPD 穩定期治療組和 COPD 穩定期對照組外週血 T 淋巴細胞Ag - NORs水平比較,差異無統計學意義( P >0.05);治療後, COPD 穩定期治療組外週血 T 淋巴細胞Ag - NORs水平高于 COPD 穩定期對照組(t =-1.647,P <0.05)。AECOPD 治療組及 COPD 穩定期治療組治療期間各齣現註射部位跼部紅腫1例,予熱敷後1週內自然消退,其他均未齣現明顯不良反應。結論 COPD 患者使用卡介菌多糖覈痠治療,可增加 T 淋巴細胞Ag - NORs水平,改善其免疫功能。
목적:탐토잡개균다당핵산대만성조새성폐질병( COPD)환자 T 림파세포핵인구산성비조단백(Ag - NORs)수평적영향。방법선택2012년1월—2013년6월귀주성인민의원호흡여위중증의학과급간부의료과수치적 COPD 급성가중기( AECOPD)환자50례급재량과실치료후 COPD 은정기환자40례。채용수궤수자표법장AECOPD 환자화 COPD 은정기환자분별분위치료조화대조조。AECOPD 급 COPD 은정기대조조환자균부급여상규치료,치료조환자재상규치료기출상가용잡개균다당핵산치료,료정균위1개월。우치료전후균대환자외주혈 T 림파세포Ag - NORs진행염색분석,이핵인은염면적/핵은염면적( I/ S%)작위 Ag - NORs 적검측지표。결과치료전, AECOPD 치료조화 AECOPD 대조조외주혈 T 림파세포Ag - NORs수평비교,차이무통계학의의(P >0.05);치료후, AECOPD 치료조외주혈 T 림파세포Ag - NORs수평고우 AECOPD 대조조(t =-1.708,P <0.05)。치료전,COPD 은정기치료조화 COPD 은정기대조조외주혈 T 림파세포Ag - NORs수평비교,차이무통계학의의( P >0.05);치료후, COPD 은정기치료조외주혈 T 림파세포Ag - NORs수평고우 COPD 은정기대조조(t =-1.647,P <0.05)。AECOPD 치료조급 COPD 은정기치료조치료기간각출현주사부위국부홍종1례,여열부후1주내자연소퇴,기타균미출현명현불량반응。결론 COPD 환자사용잡개균다당핵산치료,가증가 T 림파세포Ag - NORs수평,개선기면역공능。
Objective To detect the effects of BCG - polysaccharide nucleic acid on peripheral blood T - lymphocytes argyrophilic nucleolar organizer proteins ( Ag - NORs) in patients with chronic obstructive pulmonary disease ( COPD). Methods Fifty patients of acute exacerbation of COPD( AECOPD) were divided randomly into groups AECOPD study, AECOPD control and 40 remitting COPD(RCOPD)patients into groups RCOPD study,RCOPD control in Peopleˊs Hospital of Guizhou from january 2012 to june 2013. Four groups were given conventional treatment,the study groups given additional BCG- polysaccharide nucleic acid,the courses lasted 1 month. Taking nucleolar silver staining/ nuclear silver staining(I/ S% )as the test index of Ag - NORs,a staining analysis on peripheral blood T - lymphocyte Ag - NORs was performed before and after treatment. Results There was no significant difference in Ag - NORs level between groups AECOPD study,control before treatment(P > 0. 05),higher in AECOPD study group than in AECOPD control after treatment(t = - 1. 708,P < 0. 05). No difference was noted in Ag - NORs between groups RCOPD study,control before treatment(P > 0. 05),and higher in RCOPD study group than in RCOPD control group after treatment(t = - 1. 647,P < 0. 05). One patient from AECOPD study group and 1 from RCOPD study group had local swelling on injection sites and regressed spontaneously. No obvious adverse reactions appeared in the other patients. Conclusion BCG - polysaccharide nucleic acid can increase T - lymphocyte Ag - NORs level and improve its immune function in COPD patients.